Anti-(+)-Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction

Abstract

Anti-(+)-methamphetamine monoclonal antibodies (mAbs) have the potential to reduce the devastating behavioral and societal effects of the worldwide epidemic of (+)-methamphetamine (METH) addiction and transform the treatment paradigm for diseases of addiction. These novel, protein-based medications could play a vital role in helping patients to achieve sustainable abstinence from METH abuse by serving as an in vivo, around-the-clock sentry against a patient's vulnerability to relapse. © 2010 American Society for Clinical Pharmacology and Therapeutics.